Free Trial

Roche (RHHBY) Stock Forecast & Price Target

Roche logo
$34.50 +0.26 (+0.76%)
(As of 12/20/2024 05:55 PM ET)

Roche - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
1
Buy
1

Based on 5 Wall Street analysts who have issued ratings for Roche in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 5 analysts, 3 have given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for RHHBY.

Consensus Price Target

N/A

Get the Latest News and Ratings for RHHBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Roche and its competitors.

Sign Up

RHHBY Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
5 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
2 Sell rating(s)
Consensus Price TargetN/AN/AN/A$40.00
Forecasted UpsideN/AN/AN/A12.55% Upside
Consensus Rating
Reduce
Reduce
Reduce
Hold

RHHBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RHHBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Roche Stock vs. The Competition

TypeRocheMedical CompaniesS&P 500
Consensus Rating Score
1.60
2.81
2.51
Consensus RatingReduceModerate BuyModerate Buy
Predicted UpsideN/A25,828.59% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent RHHBY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/13/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 DowngradeHold ➝ Sell
9/13/2024Bank of America
3 of 5 stars
 UpgradeNeutral ➝ Buy
5/30/2024The Goldman Sachs Group
2 of 5 stars
 Initiated CoverageSell
3/4/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
1/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight
9/12/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$45.00 ➝ $40.00+12.71%
9/5/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
3/27/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
2/27/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
1/4/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
1/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:59 PM ET.


RHHBY Forecast - Frequently Asked Questions

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roche in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" RHHBY shares.

According to analysts, Roche's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Analysts like Roche less than other "medical" companies. The consensus rating for Roche is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RHHBY compares to other companies.


This page (OTCMKTS:RHHBY) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners